Morgan Stanley Upgrades ABIOMED (ABMD) to Overweight
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst David Lewis upgraded ABIOMED (NASDAQ: ABMD) from Equalweight to Overweight with a price target of $496.00 (from $396.00).
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $389.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- HSBC Upgrades Keurig Dr Pepper (KDP) to Buy
- Riskified Ltd. (RSKD) PT Raised to $7.50 at DA Davidson on Improving New Business Trends
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
